Thermo Fisher earnings exceeded analyst expectations in the third quarter of 2026, with adjusted earnings per share of $6.68 beating estimates by $0.28. Revenue rose 9% to $12.14 billion, about $190 million above expectations. The October 21 announcement covered the quarter ended September 26, 2026.
Key Takeaways
- Adjusted EPS rose 15%, while GAAP diluted EPS increased 9% to $4.64.
- Organic revenue grew 6%, with acquisitions and divestitures adding to reported growth.
- Both GAAP and adjusted operating margins widened by 1.2 percentage points.
Table of Contents
- Thermo Fisher earnings grow faster than sales
- Laboratory services lead an uneven segment performance
- Cash generation improves; guidance reserved for the call
- Conclusion
Thermo Fisher earnings grow faster than sales
Thermo Fisher’s third-quarter 2026 results announcement showed revenue increasing from $11.12 billion a year earlier. Its growth reconciliation attributed three percentage points to acquisitions and divestitures, with no contribution from currency translation. Organic revenue growth, a non-GAAP measure, was 6%.
GAAP operating income increased 17% to $2.26 billion, while adjusted operating income rose 15% to $2.97 billion. GAAP operating margin reached 18.6%, versus 17.4% a year earlier; adjusted operating margin increased to 24.5% from 23.3%. Operating profit therefore grew faster than revenue on both measures.
Adjusted EPS increased from $5.79 to $6.68, compared with GAAP diluted EPS of $4.64 versus $4.27. The adjusted measure excludes items including acquisition-related intangible amortization and restructuring costs, so it is distinct from the company’s reported GAAP earnings.
| Item | Details |
|---|---|
| Life Sciences Solutions revenue | $2.719 billion in Q3 2026, versus $2.588 billion in Q3 2025 |
| Analytical Instruments revenue | $2.002 billion, versus $1.893 billion |
| Specialty Diagnostics revenue | $1.098 billion, versus $1.174 billion |
| Laboratory Products and Biopharma Services revenue | $6.863 billion, versus $5.970 billion |
Laboratory services lead an uneven segment performance
Laboratory Products and Biopharma Services delivered the largest dollar increase in segment revenue. Life Sciences Solutions and Analytical Instruments also grew, while Specialty Diagnostics revenue declined.
Despite lower sales, Specialty Diagnostics increased segment income to $341 million from $321 million, with its segment margin rising to 31.0% from 27.4%. Analytical Instruments also improved profitability, lifting its segment margin to 26.9% from 22.6%.
During the quarter, Thermo Fisher completed the previously announced divestiture of its microbiology business. It also opened an AI-Automation Innovation Center in South Korea and a highly automated distribution center in Kentucky.
Cash generation improves; guidance reserved for the call
Operating cash flow increased to $2.55 billion from $2.24 billion in the prior-year quarter. Free cash flow, a non-GAAP measure, rose to $2.12 billion from $1.84 billion.
The earnings release did not include revised full-year financial targets. Thermo Fisher said it would provide updated 2026 guidance during its October 21 earnings conference call, scheduled for 7 a.m. Eastern Time. Those updated figures are not included in the supplied announcement.
Conclusion
The quarter combined above-forecast sales and adjusted earnings with wider operating margins. The updated full-year guidance reserved for the October 21 call is the next item to assess against those results.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
